Is a Cure Within Reach for Mantle Cell Lymphoma?
Studying this approach
This specific approach to mantle cell lymphoma has been published in the New England Journal of Medicine via a study in Europe of young patients, between 18 and 65, who would be eligible for the transplant. This study included those who had not previously received treatment for mantle cell lymphoma, and were now given rituximab and DHAP chemotherapy. This treatment went on for four cycles. For those who were sensitive to the aggression of the regimen, and showed either partial or complete responses, they would be randomized into rituximab maintenance or simply observation.